Protein intake is the single most important dietary factor during GLP-1 treatment
D., Butler, J., Verma, S., Joshi, P
Gastrointestinal Adverse Reactions In clinical trials in adults, 73% of WEGOVY-treated patients and 47% of patients receiving placebo reported gastrointestinal adverse reactions, including severe reactions that were reported more frequently among patients receiving WEGOVY (4.1%) than placebo (0.9%)
Maintain your usual blood glucose monitoring schedule, as this allows you to identify any changes in glycaemic control, whether related to the vaccine, your medication, or other factors
Mixing 5mg semaglutide or mixing 10mg semaglutide with bacteriostatic water requires specific ratios to achieve the target concentration